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Abstract 
Background: The node classification outlined in the seventh edition of the 
tumor-node-metastasis (TNM) classification is based solely on the number of metastasized 
lymph nodes. We examined the prognostic value of apical lymph node metastasis and the 
additive value of incorporating apical lymph node status into a risk model based on the 
seventh edition. 
Methods: Our cohort study involved 1355 patients with Stage III colon cancer who 
underwent tumor resection with dissection of regional (including apical) lymph node at 71 
hospitals across Japan between 2000 and 2002. The main exposure was pathologically 
confirmed apical lymph node metastasis, and the primary endpoint was cancer-specific death.  
Results: Apical lymph node metastasis was present in 113 (8.3%) of the patients. During 
5,356 patient-years (median 5.0 year) of follow-up, 221 (16.3%) instances of cancer-specific 
death were observed. After adjustment for tumor and node classification (as described in the 
seventh edition) and other prognostic factors, apical lymph node metastasis was found to be 
independently associated with cancer-specific death (hazard ratio, 2.29; 95% confidence 
interval [CI], 1.49-3.52). Incorporating apical lymph node metastasis into the prognostic 
model based on the seventh TNM edition significantly improved discriminative performance 
for cancer-specific death (difference in concordance index, 0.0146; 95% CI, 0.003-0.026) and 
risk reclassification for cancer-specific death at 5 years (category free net reclassification 
improvement, 19.4%; 95% CI, 5.0%-33.4%), respectively. 
Conclusions: Assessment of apical lymph node metastasis provided independent prognostic 
information beyond that achievable with the seventh TNM edition in patients with Stage III 
colon cancer.  
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Introduction 
Accurate prognostic estimation of colorectal cancer is important for facilitating accurate 
decision-making in oncological management. The tumor-node-metastasis (TNM) 
classification developed by the American Joint Committee on Cancer (AJCC) and the Union 
for International Cancer Control (UICC) is the most commonly used staging system 
worldwide. Under this system, lymph node staging is defined based only on the number of 
metastatic lymph nodes,1 representing an extremely simple way of classifying patients and 
saving surgeons or pathologists the trouble of classifying retrieved lymph nodes by 
anatomical location, such as paracolic area, intermediate area, or apical area. However, 
anatomical location of lymph nodes remains an important point from a prognostic perspective, 
especially given that apical lymph nodes (ALNs) are considered the entry point for lymph 
node metastases further proximal to the aorta (such as the para-aortic lymph node) or for 
hematogenous metastasis. As such, although ALN metastases have high potential utility as a 
marker for prediction of future systemic metastasis and subsequent mortality, whether or not 
ALN metastasis has such prognostic value remains unclear. 
Several previous studies support the notion that the location of the metastasized lymph 
node has prognostic value. For example, presence of inferior mesenteric artery lymph node 
metastasis has been shown to predict para-aortic nodal recurrence in sigmoid colon and rectal 
cancer patients.2 Other studies have shown distribution of lymph node metastasis to be an 
independent predictor of overall survival for sigmoid colon and rectal cancer.3, 4 However, 
these previous studies were limited by the disease being restricted to a partial area of the 
colon and by being single-center studies. Further, these studies failed to show the value of 
incorporating the location of the metastasized lymph node into existing TNM 
classification-based prediction models. 
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Here, using Japanese multicenter registry data, we examined the association between 
ALN metastasis with cancer-specific death among colon cancer patients as well as assessed 
whether or not the addition of ALN metastasis to the prognostic model based on the seventh 
edition of the UICC TNM staging system (UICC7) improves discrimination of 
cancer-specific death.  
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Method 
We obtained approval to use the registry data of Japanese Society for Cancer of the Colon and 
Rectum (JSCCR) in our cohort study. The JSCCR registry project was approved by the 
institutional review board of Tochigi Cancer Center. Patients diagnosed with colorectal cancer 
who underwent surgery at 89 member hospitals across different areas in Japan between 
January 2000 and December 2002 were voluntarily registered in the JSCCR registry. This 
nationwide registry is hospital-based (not population-based) and covers approximately 6.5% 
of all patients with colorectal cancer in Japan between 2000 and 2002. Eligibility criteria for 
this study were (1) patients with colon cancer who underwent curative resection with 
dissection of regional lymph node including ALN, (2) pathologically diagnosed Stage III with 
colon cancer, and (3) no distant metastasis. To maintain comparability between patients with 
or without ALN metastasis, neither Stage 0, I, nor II was included in the present study, as no 
patients in any of those Stages have ALN metastasis. Whether or not distant metastasis is 
present is usually examined using a combination of chest X-ray, abdominal ultrasound, and 
abdominal (and chest) computed tomography.5 Exclusion criteria were (1) patients who 
underwent preoperative treatment or (2) patients with multiple primary cancers. We also 
excluded patients with rectal cancer, which was defined as cancer of the bowel below the 
lower margin of the second sacral vertebra,6 as these patients have two main lymphatic 
drainage routes. Specifically, both routes continuing to the root of the inferior mesenteric 
arteries and the internal iliac arteries are involved in lymphatic spread. To correctly determine 
ALN metastasis, bilateral lymph node dissection surrounding the root of the internal iliac 
arteries is required but is not always performed in actual practice, as it is often complicated by 
voiding or sexual dysfunction. As informed consent to use existing registry data is not 
mandatory for observational studies in Japan, such consent was not obtained for this study. 
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Lymph node staging and apical lymph node metastasis 
For the JSCCR registry, data on number and anatomical location of positive lymph node were 
collected, while only the anatomical location of positive lymph nodes had been used for 
staging according to the Japanese Classification of Colorectal Carcinoma between 2000 and 
2002. For the present study, using data on the number of positive lymph nodes, lymph node 
staging was defined according to the UICC version 7 (UICC7) and classified into four 
categories: N1a, N1b, N2a, and N2b.1 The category of N1c was excluded because tumor 
deposit was not registered in the Japanese Classification system at that time. The definition of 
ALNs corresponds to the N3 station in the Japanese Classification of Colorectal Carcinoma, 
which locates the roots of major arteries, such as the iliocecal artery, right colic artery, middle 
colic artery, or inferior mesenteric artery.6 These lymph node metastases were considered to 
be present if the retrieved lymph nodes were found to be metastasized pathologically. In Japan, 
well-trained surgeons usually perform regional lymph node dissection involving dissection of 
ALN, and surgeons in the theatre assign lymph node stations during surgery or 
postoperatively, in accordance with rules of Japanese classification of colorectal cancer.6 Fat 
clearance technique is not generally performed. 
 
Cancer-specific death 
Cause of death was categorized as defined by the JSCCR as death related to surgery, death 
specifically related to colon cancer, death related to other primary cancer, death not related to 
cancer, death of unknown cause. This outcome ascertainment is routine with the JSCCR 
registry and was performed independent of the study. Death specifically related to colon 
cancer was defined as the primary outcome and referred to as “cancer-specific death”. 
Follow-up started from post-operative day 1 and ended on the date of death or the date of the 
patient’s final visit to the hospital. In Japan, given that patients receiving curative resection 
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generally continue regular outpatient visits for at least five years5 and patients are hospitalized 
before dying, most deaths were able to be collected through dedicated follow-up by surgeons. 
 
Measurement of other covariates 
Other clinical variables potentially useful in predicting cancer-specific death used in the 
present study were age, gender, histological type, and pathological T category. Histological 
type was dichotomized as “well or moderately differentiated” and “poorly differentiated, 
signet ring cell, or mucinous”. Pathological T category was classified into four categories 
according to the seventh TNM classification: T1/T2, T3, T4a, and T4b. 
 
Statistical analysis 
All statistical analyses were conducted using R version 2.13.1 (www.r-project.org) and Stata 
version 11.0 (Stata Corp., College Station, TX, USA). Demographic characteristics, 
histological type, pathological T category, UICC7-based lymph node staging, presence of 
ALN metastasis, and number of retrieved lymph nodes were described. Continuous variables 
and categorical variables were summarized as median (with 10th to 90th percentiles) and 
percent, respectively. 
Cancer-specific death during the follow-up period was described as number, proportion, 
and incidence rate. Cancer-specific survival curves for those with and without ALN 
metastasis were estimated using Kaplan-Meier method, and difference between the two was 
assessed via the log-rank test. These analyses were stratified by each category of 
UICC7-based lymph node staging. 
Effect measures in the present study were hazard ratios (HRs) for cancer-specific death 
using Cox models. Two models were constructed: a risk model of UICC7 based lymph node 
staging (Model 1) and a risk model of UICC7-based lymph node staging plus ALN status 
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(Model 2). To estimate adjusted HRs, all of the covariates described above were forced into 
multivariate analyses. Facility clustering effects of these analyses were addressed using a 
robust variance estimator,7 and the proportional hazards assumption was tested and verified 
for each covariate. 
Discrimination for the two risk models was conducted using Harrell’s c index, which is 
similar to the area-under-the-curve statistic for receiver-operating characteristic plots but 
allows calculation of concordance in time to event data. The c-indices of the two risk models 
and their difference were calculated with 2,000-replication bootstrapping, and bias-corrected 
95% confidence intervals (95% CIs) were reported. Both the bootstrapping technique used in 
the present paper and the data-splitting technique estimate the likely performance of the 
prediction model on a new sample of patients from the present patient population.8 However, 
the bootstrapping technique is more efficient than the data-splitting technique in that it 
preserves the sample size, improving precision and power.9, 10 Thus, 95% CIs for the c-indices 
of the two risk models and their difference can be viewed as validated discrimination 
measures applied to a new sample from the same population.9, 10 
The predicted risk of cancer-specific death at five years was estimated from a Cox 
model containing UICC7-based variables alone or UICC7-based variables plus ALN status. 
The predicted risk was determined by first running a Cox model to obtain the baseline 
survival function at five years, expressed as S0(5).11 A risk score for each value of 
UICC7-based variables, with or without ALN status, was then calculated by multiplying the 
observed value for the model parameter by its corresponding coefficient from the Cox model. 
The estimated probability of observing cancer-specific death at five years was then calculated 
using the formula: P(5)=1 - S0(5)×exp(risk score). 
The potential for ALN status to improve risk prediction beyond a UICC7-based risk 
model (Model 1) for cancer-specific death was further assessed based on category-free net 
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reclassification improvement (NRI) and integrated discrimination improvement (IDI) as, to 
date, clinically relevant cut-off values for the risk of cancer-specific death are absent among 
patients with colon cancer, and both category-free NRI and IDI are independent of arbitrarily 
defined risk thresholds.12 Category-free NRI is a measure for estimating overall improvement 
in reclassification of patients on incorporating ALN status into the UICC7-based risk model 
and is calculated as the net proportion of patients whose predicted risk improved among those 
with (case) and without (control) cancer-specific death. For each patient, the predicted risk of 
cancer-specific death at five years was determined using the UICC7-based risk model, and the 
relative improvement in patient reclassification associated with ALN metastasis was then 
assessed. In contrast, IDI is a measure for examining the ability of ALN status added to the 
UICC7-based risk model to increase average sensitivity without reducing average specificity12 
and is calculated as improvement in the difference in the predicted risk between patients with 
(case) and without (control) cancer-specific death. Any events outside the five-year time 
frame were censored. Patients with censored data were treated as controls.  
We also conducted sensitivity analyses. (1) Cancer-specific death was evaluated using 
patients with complete data, considering deaths other than cancer-specific death as competing 
risk according to the competing-risk regression model developed by Fine and Grey.13 (2) 
Cancer-specific death was analyzed by imputing missing covariate and lymph node staging 
values. Multiple imputation using a chained equations method was used for estimating 
adjusted HRs,14, 15 with results showing that 162 participants (10.7%) had missingness. 
Multiple imputation with five imputed datasets using aregImpute function in the Hmsisc 
package was used for estimating difference in c-indices of the two risk models, category-free 
NRI, and IDI.16 (3) All-cause death was analyzed using patients with complete data. P<0.05 
was considered statistically significant. 
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Results 
Of the 17,739 patients in the registry, 9,378 with primary colon cancer underwent curative 
resection (Figure 1). Of those, 2,840 had Stage III disease, with at least 1,593 undergoing 
regional lymph node dissection involving ALN (277 underwent lymph node dissection of 
unknown extent). After excluding 76 (for missing data for survival time) and 162 patients (for 
either or both missing data for number of lymph node metastases [159] or having at least one 
confounding variable missing [11]), the remaining 1,355 with Stage III primary colon cancer 
who underwent regional lymph node dissection from 71 facilities were ultimately entered into 
primary analyses (85.1% of Stage III disease patients with regional lymph node dissection). 
Baseline characteristics of patients are presented in Table 1. Median age was 65 years. Well 
or moderately differentiated adenocarcinoma was the dominant histological type (91.0%). The 
most commonly assigned categories for pathological T and lymph node staging were T3 
(55.4%) and N1a (39.4%), respectively. The median number of retrieved lymph nodes was 
19. 
Baseline characteristics were similar between participants with and without missing 
confounding variables or lymph node staging data (Table S1) except for lymph node staging 
and apical lymph node metastasis. As a group, their age, distribution of gender, distribution of 
histological type, and distribution of pathological T category were similar.  
 Overall, ALN metastasis was present in 8.3% (N=113) of patients. Respective 
proportions of apical lymph node metastasis were 2.1% (N=11), 7.1% (N=33), 10.2% (N=23), 
and 35.7% (N=46) among those with N1a, N1b, N2a, and N2b, respectively. As a group, 
patients with ALN metastasis had poorer histological type and more advanced pathological T 
and lymph node staging than those without metastases, whereas median number of retrieved 
lymph nodes were similar, regardless of ALN metastasis (Table 1). 
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 Over the course of this study, a total of 5,356 patient-years (mean, 4.0 years; median, 
5.0 years) and 221 (16.3%) instances of cancer-specific death were observed, giving an 
incidence rate of cancer-specific death of 4.13 per 100 patient-years. Overall, cancer-specific 
survival at 5 years was 81.0%. When stratified based on UICC7-based lymph node staging, 
cancer-specific survival at 5 years was worse among patients with ALN metastasis than 
among those without it (Figure 2), with respective survival rates of 67.5% and 87.5% for N1a 
(log-rank test P=0.068), 62.5% and 83.3% for N1b (P=0.003), 49.8% and 83.0% for N2a 
(P<0.001), and 37.2% and 61.1% for N2b (P=0.008).  
 Associations between two lymph node staging models and cancer-specific death, 
described in Table 2, were slightly attenuated after adjustment for covariates. For Model 1, 
N2b was associated with higher cancer-specific death rate than N1a (adjusted HR, 3.86; 95% 
CI, 2.28-6.53). For Model 2, N2b was still associated with higher cancer-specific death rate 
than N1a, but slightly more weakly than seen in Model 1 (adjusted HR, 2.98; 95% CI, 
1.73-5.12). In the same model, the presence of ALN metastasis was associated with an 
increased cancer-specific death rate (adjusted HR, 2.29; 95% CI, 1.49-3.52). Sensitivity 
analyses in which non-cancer-specific deaths were considered competing risks showed that 
adjusted HRs of lymph node staging and ALN metastasis were similar to those presented in 
Table 2 (Table S2). We therefore chose the Cox models for primary analysis of 
cancer-specific death and based further analyses on these models. 
Concordance indices and differences in them between these two risk models are 
presented in Table 3. Harrell’s c statistics were 0.694 and 0.708 for the risk model based on 
UICC7 and the risk model based on UICC7 and ALN status, respectively, and the latter was 
better than the former (difference, 0.014; 95% CI, 0.005-0.030), suggesting that the risk 
model based on UICC7 and ALN has better performance of discrimination than one based on 
UICC7 alone. 
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Reclassification of risk was assessed for cancer-specific death after addition of ALN 
status to the risk model based on UICC7 (Table 4). Both of the risks predicted using the 
UICC7-based model with or without addition of ALN status at the individual level were 
visualized as plots (Figure S1). Addition of ALN status to the UICC7-based model resulted in 
28.5% correct (up) reclassifications and 71.5% incorrect (down) reclassifications in the 221 
patients with cancer-specific death. In contrast, 81.2% correct (down) reclassifications and 
18.8% incorrect (up) reclassifications were noted in the 1134 patients without cancer-specific 
death. Overall, 19.4% of patients were correctly reclassified on addition of ALN status 
(category-free NRI, 19.4% [95% CI, 5.0%-33.4%; P=0.008]). Further, addition of ALN status 
to the UICC7-based model significantly improved stratification between the patients with 
cancer-specific death and those without it (IDI, 0.0146 [95% CI, 0.003-0.026; P=0.014]), 
indicating that the difference in average predicted risk between patients with cancer-specific 
death and those without increased by 0.0146 on incorporation of ALN status into the 
UICC7-based risk model. 
In sensitivity analyses using imputed data for 1,517 participants, adjusted HR of ALN 
status for cancer-specific death (Table S3), the difference in the c-indices of the two risk 
models (Table S4), category-free NRI, and IDI (Table S5) were similar. When all-cause death 
was analyzed among the 1,355 patients, 290 (21.4%) of all-cause death was observed (overall 
survival at 5 years: 76.0%). The results were similar to those for cancer-specific death (Figure 
S2; Table S6; Table S7; and Table S8). 
  
Discussion 
In this multicenter cohort study of stage III colon cancer patients, pathologically-confirmed 
ALN metastasis was independently associated with cancer-specific death. In addition, 
incorporating ALN metastasis into the seventh TNM classification-based prognostic model 
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significantly improved risk reclassification for cancer-specific death. Results were similar 
when all-cause death was examined as an outcome. Our findings suggest that identification of 
ALN metastasis by anatomical classification may provide additional prognostic value for risk 
stratification of cancer-specific death for patients with colon cancer.  
Findings from several previous studies support the prognostic value of anatomical 
classification of the metastasized lymph nodes. Indeed, one study showed that the inferior 
mesenteric artery (IMA) lymph node metastasis (i.e. an apical lymph node metastasis) was 
associated with para-aortic nodal recurrence.2 However, participants in this previous study 
were restricted to patients with sigmoid colon and rectal cancer, and the association between 
IMA lymph node metastasis and mortality was not examined. Another study showed that 
anatomical classification of metastasized lymph node was independently associated with 
overall survival among patients with sigmoid colon and rectal cancer.3 The importance of 
anatomical classification of metastasized lymph nodes in predicting overall survival was also 
shown among patients with colon or rectal cancer.4, 17 However, these previous studies 
involve several shortcomings, such as their single-center status, the fact that most had 
relatively small sample size, their therapeutic heterogeneity (especially adjuvant 
chemotherapy), and most importantly, their failure to examine the additive value of 
incorporating the anatomical classification of the metastasized lymph nodes into the existing 
TNM classification-based risk model. Our multicenter study involved 1355 patients with any 
portion of the Stage III colon cancer patients from more than 71 facilities. In addition, we 
focused on the prognostic importance of ALN metastasis and showed that incorporating the 
ALN into the seventh TNM classification based risk model significantly improved predictive 
ability for both cancer-specific and all-cause death.  
We feel that our findings here will influence the activities of surgeons and cancer 
researchers for several reasons. First, a more accurate staging system enables surgeons to 
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provide detailed information to postoperative patients. Further, identification of those 
subgroups with a relatively poor prognosis may indicate necessity of more extensive adjuvant 
therapy to such patients. Second, our findings may represent a basis for conducting a future 
study examining the effectiveness of dissecting ALNs for colorectal cancer. The ALNs are 
considered the entry point for lymph node metastases further proximal to the aorta (such as 
the para-aortic lymph node) or for hematogenous metastasis, and therefore their retrieval may 
offer prognostic benefit. Indeed, complete mesenteric excision (CME) including ALN has 
been proposed as a method of improving oncological outcomes.18 However, CME is often 
associated with a greater technical requirement, involving high ligation of a major artery, and 
might therefore increase incidence of postoperative complications. Further study is therefore 
warranted to clarify the role of CME in apical lymph node dissection. Third, the present study 
demonstrated that the TNM classification can be restructured based on the evidence to predict 
patient prognosis better by incorporating ALN metastasis into the risk model based on the 
present TNM classification.19 Of note, ALN was an important feature in the lymph node 
staging in the fourth TNM classification but has since been dropped from the fifth TNM 
classification due to presumed lack of importance.20 The seventh TNM classification has 
come under criticism due to lack of an evidence base for changing the definitions of 
classifications (e.g. tumor deposits) from previous editions [check – is this what you 
mean?<-- How is this? Tumor deposits is one example of “definition of classification” and is 
not main theme in the present study.].21 Further studies regarding the additive impact of 
pathological findings on prognosis prediction will be required to revise the TNM 
classification scientifically.  
Several strengths to the present study warrant mention. First, this cohort study was 
conducted using a nationwide registry of major teaching hospitals across different areas of 
Japan, and our survival analyses accounted for variability in survival across the facilities 
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using a robust variance estimator.7 Our study design and analysis plan ensures the 
generalizability of our findings. Second, the relatively short, uniform enrollment period 
prevented our findings from being confounded by advances in perioperative management or 
development of new anti-cancer agents such as oxaliplatin, which were not marketed in Japan 
between 2000 and 2002. Third, the association between ALN metastasis and cancer-specific 
death might be less likely to be affected by competing risks because Japanese patients tend to 
experience fewer cardiovascular disease risks than patients in Western countries.22 Indeed, 
results for sensitivity analyses with all-cause death as the outcome were similar to those in 
primary analyses. Fourth, by calculating the difference in the c-indices, category-free NRI, 
and IDI, we were able to demonstrate that incorporating ALN status into the seventh TNM 
classification-based risk model not only improved the discriminative performance but also 
improved accuracy in risk reclassification for cancer-specific death and all-cause death. 
However, several limitations to the present study warrant mention. We were unable to 
incorporate other potential confounders such as tumor markers or degree of lymphatic vessel 
invasion or vascular invasion, which might have resulted in overestimation of the strength in 
the association between ALN metastasis and cancer-specific death. In addition, we were 
unable to incorporate the use of adjuvant chemotherapy. However, lack of adjustment for 
adjuvant chemotherapy tends to result in underestimation of the strength of the association 
between ALN metastasis and cancer-specific death, as adjuvant chemotherapy is more likely 
to be provided to those with more advanced lymph node staging involving ALN. Second, we 
were unable to incorporate N1c category of the seventh TNM classification in the present 
study, as tumor deposit was not used for staging between 2000 and 2002. Further study is 
warranted to examine the prognostic value of ALN metastasis. Third, among the patients 
experiencing cancer-specific death, the risk model based on UICC-7 based variables plus 
ALN status proved less accurate in its predictability than the model based on UICC-7 alone, 
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although ALN metastasis itself was an independent prognostic factor. Further research is 
needed to construct a more precise risk model.  
In conclusion, ALN metastasis is a significant prognostic factor in stage III colon cancer, 
and integration of ALN into the seventh TNM classification-based risk model improves 
accuracy of prediction of prognosis. ALN should therefore be incorporated into the next TNM 
classification to better stratify patient prognosis.  
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Figure 1. Flow chart of the study population.  
JSCCR: Japanese Society for Cancer of the Colon and Rectum.  
 
Figure 2. Description of cancer-specific survival by UICC7-based lymph node staging 
and apical lymph node status.  
Cancer-specific survival curves were estimated via the Kaplan-Meier method. Within each 
UICC7-based lymph node staging (i.e. N1a to N2b), survival curves are shown based on apical 
lymph node status. Solid and dashed lines indicate survival curves for those with and without 
apical lymph node metastasis, respectively. ALN: Apical lymph node metastasis, (-): Absent, 
(+): Present. 
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Table 1. Baseline characteristics of the analysis population  
 Total 









Age, y    
Median 65 65 67 
10th to 90th percentile 50 to 77 50 to 77 51 to 77 
Gender, n (%)    
Men 704 (52.0) 655 (52.7) 49 (43.4) 
Women 651 (48.0) 567 (47.3) 64 (56.6) 
Histological type, n (%)    
Well or moderately differentiated 1,233 (91.0) 1,145 (92.2) 88 (77.9) 
Poorly differentiated/Signet ring 
cell/Mucinous 
122 (9.0) 97 (7.8) 25 (22.1) 
Pathological T category, n (%)    
T1/2 100 (7.4) 96 (7.7) 4 (3.5) 
T3 750 (55.4) 700 (56.4) 50 (44.3) 
T4a 424 (31.3) 377 (30.4) 47 (41.6) 
T4b 81 (6.0) 69 (5.6) 12 (10.6) 
Lymph node staging according to 
UICC7, n (%) 
   
N1a 534 (39.4) 523 (42.1) 11 (9.7) 
N1b 466 (34.4) 433 (34.9) 33 (29.2) 
N2a 226 (16.7) 203 (16.3) 23 (20.4) 
N2b 129 (9.5) 83 (6.7) 46 (40.7) 
Apical lymph node metastasis 
(ALN), n (%) 
   
Absent 1,242 (91.7)   
Present 113 (8.3)   
Number of retrieved lymph nodes, n    
Median 19 19 18 
10th to 90th percentile 8 to 40 8 to 40 7 to 39 
UICC7: Union for International Cancer Control version 7 
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Table 2. Association between lymph node staging and cancer-specific death (N=1,355) 




HR (95% CI) p-value  
Adjusteda 
HR (95% CI) p-value 
Model 1: UICC7       
Lymph node staging       
N1a 534 Reference   Reference  
N1b 466 1.41 (0.98 - 2.01) 0.061  1.38 (0.94 - 2.02) 0.102 
N2a 226 1.63 (1.06 - 2.52) 0.026  1.49 (0.97 - 2.29) 0.069 
N2b 129 4.74 (2.91 - 7.71) <0.001  3.86 (2.28 - 6.53) <0.001 
Model 2: UICC7 + ALN status       
Lymph node staging       
N1a 534 Reference   Reference  
N1b 466 1.32 (0.93 - 1.89) 0.123  1.31 (0.89 - 1.93) 0.166 
N2a 226 1.49 (0.97 - 2.28) 0.066  1.39 (0.91 - 2.12) 0.128 
N2b 129 3.47 (2.13 - 5.66) <0.001  2.98 (1.73 - 5.12) <0.001 
Apical lymph node metastasis       
Absent 1,242 Reference   Reference  
Present 113 2.58 (1.76 - 3.78) <0.001  2.29 (1.49 - 3.52) <0.001 
aEstimated from Cox models including age, gender, histological type, and pathological T stage accounting for facility clustering effects 
HR: hazard ratio, CI: confidence interval, UICC7: Union for International Cancer Control version 7, ALN: apical lymph node 
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Table 3. Concordance indicies and their difference between the two prognostic models 
for cancer-specific death (N=1,355)a 
 Cancer-specific death 
Harrell’s C (95% CIb) 
Model 1: UICC7 0.694 (0.651 - 0.724) 
Model 2: UICC7 + ALN status 0.708 (0.666 - 0.737) 
  
 Difference in Harrell's C (95% CIb) 
Model 2 vs. Model 1 0.014 (0.005 - 0.030) 
aDerived from Cox models including age, gender, histological type, pathological T stage, and 
lymph node staging presented in Table 2, accounting for facility clustering effects.  
bConfidence intervals were calculated from 2,000 replication bootstrapping with bias 
correction method. In one re-sampling with a new set of 1,355 patients (some were able to be 
re-sampled twice or more), we computed point estimates of c-indices (Harrell’s c) from model 
1 (C1) and from model 2 (C2) and determined difference in the two c-indices. The point 
estimate of difference in the c-indices is “C2 – C1” and indeed this was positive (over zero) in 
our analyses. By replicating this process 2,000 times, we obtained 2,000 estimates of C1, C2 
and “C2 – C1”. From the 2,000 estimates, we obtained the 95% CIs presented in Table 3. 
Therefore, even though 95% CIs of c-indices for model 1 and model 2 did overlap to some 
extent, 95% CIs of difference in the two indices were over zero. 
CI: confidence interval, UICC7: Union for International Cancer Control version 7, ALN: 
apical lymph node  
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Table 4. Category-free net reclassification improvement and integrated discrimination 
index for apical lymph node status added to the UICC7-based risk model for 
cancer-specific death at 5 years (N=1,355) 
NRI  
Cases reclassified to higher risk 28.5% 
Cases reclassified to lower risk 71.5% 
Controls reclassified to lower risk 81.2% 
Controls reclassified to higher risk 18.8% 
Category-free net reclassification 
improvement 19.4% (95% CI: 5.0%-33.4%); p=0.008 
IDI 0.0146 (95% CI: 0.0030-0.0262); p=0.014 
Cases denote patients who experienced cancer-specific death at 5 years whereas controls 
denote those who did not experience cancer-specific death at 5 years or were censored before 




(registered to the JSCCR 
registry 2000-2002)
Excluded (N=162)
Number of lymph node metastasis missing (N=159) or 
at least one covariate missing (N=11)
Excluded (N=4,661)
Not receiving curative resection (N=2,637)
Multiple primary cancer (N=1,858)
Jejunal, ileal, or anal canal cancer (N=144)
Rectal cancer (N=3,700)
Not epithelial origin (e.g. carcinoid) (N=22)
2,840 Patients with 
Stage III disease 
1,355 Patients with




Stage IV disease (N=825)
Stage I or II disease (N=5,152) 






Receiving preoperative treatment (N=27)
Receiving lymph node dissection without ALN (N=943)
Unknown extent of lymph node dissection (N=277) 
1,593 Patients with
Stage III disease 
receiving regional lymph 
node dissection 
Excluded
Survival time missing (N=76) 
1,517 Patients with
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